Junshi’s COVID Antiviral Superior To Paxlovid? Some Caveats Unveiled

 
• By Dexter Jie Yan
  
clinical trial progress
Junshi's claim of antiviral win over Paxlovid in head-to-head trial seems on shaky ground • Source: Alamy

More from China

More from Focus On Asia